Boardroom Alpha
Boardroom Alpha
AVNS · Additional Proxy Materials (DEFA14A) · Filed March 12, 2026

Avanos Medical Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
March 12, 2026
Ticker
AVNS
Accession
0001104659-26-027111
Boardroom Alpha · Filing insights

Avanos Medical, Inc.'s 2026 proxy materials show routine director elections; no contest disclosed; board recommends actions.

About Avanos Medical Inc
Market cap
$1.2B
1Y TSR
+100.8%
3Y TSR
−0.9%
Board grade
C
Sector
Healthcare
CEO
David Pacitti
Last annual meeting: Apr 21, 2026 · View full Avanos Medical Inc profile →

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.  )

 

 

  

x   Filed by the Registrant ¨ Filed by a Party other than the Registrant

 

Check the appropriate box:

 

Preliminary Proxy Statement

¨ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2))
¨ Definitive Proxy Statement
x Definitive Additional Materials
¨ Soliciting Material Under Rule 14a-12

Avanos Medical, Inc.

(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if Other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

x No fee required.
¨ Fee paid with preliminary materials.
¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

 

 

 

GRAPHIC

Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V87463-P45605 AVANOS MEDICAL, INC. 2026 Annual Meeting Vote by April 20, 2026 11:59 p.m. Eastern Time AVANOS MEDICAL, INC. 5405 WINDWARD PARKWAY ALPHARETTA, GA 30004 You invested in AVANOS MEDICAL, INC. and it’s time to vote! You have the right to vote on the proposals being presented at the 2026 Annual Meeting. This is an important notice regarding the availability of proxy materials for the Annual Meeting of Stockholders to be held on April 21, 2026. Get informed before you vote View the Combined Proxy Statement/2025 Annual Report online OR you can receive a free paper or email copy of the materials by requesting them prior to April 7, 2026. If you would like to request a copy of the materials for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy of the materials. Vote in Person at the Meeting* April 21, 2026 9:00 a.m. Eastern Time 5405 Windward Parkway Alpharetta, GA 30004

GRAPHIC

Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V87464-P45605 Voting Items Board Recommends THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the 2026 Annual Meeting of Stockholders. Please follow the instructions on the reverse side to vote on these important matters. 1. Election of Directors (to serve until the 2027 Annual Meeting). Nominees: 1a. Gary D. Blackford For 1b. William P. Burke For 1c. James L. Cunniff For 1d. Dr. Lisa Egbuonu-Davis For 1e. Indrani L. Franchini For 1f. Patrick J. O’Leary For 1g. David C. Pacitti For 1h. Dr. Julie Shimer For 2. Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for 2026. For 3. Advisory vote to approve named executive officer compensation. For 4. Approval of an amendment to the Company’s 2021 Long Term Incentive Plan to allow for the issuance of awards thereunder to the Company’s outside directors. For

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Avanos Medical Inc (AVNS)

Reference

Frequently asked questions

When did Avanos Medical Inc file this DEFA14A?
Avanos Medical Inc (AVNS) filed this Additional Proxy Materials (DEFA14A) with the SEC on March 12, 2026. The accession number assigned by EDGAR is 0001104659-26-027111.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Avanos Medical, Inc.'s 2026 proxy materials show routine director elections; no contest disclosed; board recommends actions. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Avanos Medical Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Avanos Medical Inc has filed under CIK 1606498, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer